These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16620052)

  • 1. Actin bundling protein fascin expression in ovarian neoplasms: comparison of histopathologic features of tumors obtained by the first and secondary cytoreduction surgeries.
    Kabukcuoglu S; Ozalp SS; Oner U; Bildirici K; Yalcin OT; Oge T; Colak E
    Eur J Gynaecol Oncol; 2006; 27(2):123-8. PubMed ID: 16620052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of actin bundling protein fascin in the progression of ovarian neoplasms.
    Kabukcuoglu S; Oner U; Ozalp SS; Bildirici K; Yalcin OT; Colak E
    Eur J Gynaecol Oncol; 2006; 27(2):171-6. PubMed ID: 16620064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased expression of fascin, motility associated protein, in cell cultures derived from ovarian cancer and in borderline and carcinomatous ovarian tumors.
    Hu W; McCrea PD; Deavers M; Kavanagh JJ; Kudelka AP; Verschraegen CF
    Clin Exp Metastasis; 2000; 18(1):83-8. PubMed ID: 11206843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fascin in ovarian epithelial tumors.
    Kostopoulou E; Daponte A; Terzis A; Nakou M; Chiotoglou I; Theodosiou D; Chatzichristodoulou C; Messinis IE; Koukoulis G
    Histol Histopathol; 2008 Aug; 23(8):935-44. PubMed ID: 18498068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fascin and EMMPRIN expression in primary mucinous tumors of ovary: a tissue microarray study.
    Alici O; Kefeli M; Yildiz L; Baris S; Karagoz F; Kandemir B
    Pathol Res Pract; 2014 Dec; 210(12):934-8. PubMed ID: 25155376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [How to increase the optimal rate of secondary cytoreductive surgery in recurrent epithelial ovarian cancer].
    Li YF; Li MD; Liu FY; Liu JH; Li JD
    Ai Zheng; 2003 Nov; 22(11):1193-6. PubMed ID: 14613651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary surgical cytoreduction for advanced epithelial ovarian cancer. Patient selection and review of the literature.
    Bristow RE; Lagasse LD; Karlan BY
    Cancer; 1996 Nov; 78(10):2049-62. PubMed ID: 8918397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
    Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
    Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Actin-binding protein fascin expression in skin neoplasia.
    Goncharuk VN; Ross JS; Carlson JA
    J Cutan Pathol; 2002 Aug; 29(7):430-8. PubMed ID: 12139639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary cytoreduction for ovarian cancer following cisplatin therapy.
    Segna RA; Dottino PR; Mandeli JP; Konsker K; Cohen CJ
    J Clin Oncol; 1993 Mar; 11(3):434-9. PubMed ID: 8445417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal access surgery compared to laparotomy for secondary surgical cytoreduction in patients with recurrent ovarian carcinoma: Perioperative and oncologic outcomes.
    Eriksson AGZ; Graul A; Yu MC; Halko A; Chi DS; Zivanovic O; Gardner GJ; Sonoda Y; Barakat RR; Abu-Rustum NR; Leitao MM
    Gynecol Oncol; 2017 Aug; 146(2):263-267. PubMed ID: 28527673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of fascin expression in endometrioid carcinoma.
    Kabukcuoglu S; Oner U; Ozalp SS; Dundar E; Yalcin OT; Colak E
    Eur J Gynaecol Oncol; 2006; 27(5):481-6. PubMed ID: 17139983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fascin expression in serous tumors of ovary correlates with aggressiveness of malignancy.
    Wen YH; Yee H; Goswami S; Shukla PS
    Int J Gynecol Pathol; 2009 Mar; 28(2):187-92. PubMed ID: 19188814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary cytoreductive surgery in recurrent epithelial ovarian cancer: A prognostic analysis with 103 cases.
    Fan XM; Zhang J; Niu SH; Li KX; Song CZ
    Int J Surg; 2017 Feb; 38():61-66. PubMed ID: 28027999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma.
    Hoskins WJ; Rubin SC; Dulaney E; Chapman D; Almadrones L; Saigo P; Markman M; Hakes T; Reichman B; Jones WB
    Gynecol Oncol; 1989 Sep; 34(3):365-71. PubMed ID: 2548935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
    Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
    J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
    Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of secondary cytoreductive surgery in epithelial ovarian malignancies.
    Williams L
    Oncology (Williston Park); 1992 Aug; 6(8):25-32; discussion 37-9. PubMed ID: 1386995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.
    Ghisoni E; Katsaros D; Maggiorotto F; Aglietta M; Vaira M; De Simone M; Mittica G; Giannone G; Robella M; Genta S; Lucchino F; Marocco F; Borella F; Valabrega G; Ponzone R
    J Ovarian Res; 2018 May; 11(1):42. PubMed ID: 29843747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of mesothelin, fascin, and prostate stem cell antigen in primary ovarian mucinous tumors and their utility in differentiating primary ovarian mucinous tumors from metastatic pancreatic mucinous carcinomas in the ovary.
    Cao D; Ji H; Ronnett BM
    Int J Gynecol Pathol; 2005 Jan; 24(1):67-72. PubMed ID: 15626919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.